SUTRO BIOPHARMA, INC. Accounts Payable
SUTRO BIOPHARMA, INC. (STRO) had Accounts Payable of $3.36 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $3.36M.
- 2026-03-31: Accounts Payable, Current $5.49M.
- 2025-12-31: Accounts Payable, Current $7.57M.
- 2025-09-30: Accounts Payable, Current $7.03M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.36M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $5.49M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $7.57M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $7.03M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $4.31M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $8.18M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $10.47M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $6.22M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $6.09M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $7.51M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $9.44M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $5.53M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $3.86M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $5.06M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $4.80M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $12.44M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $12.57M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $10.71M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $6.01M 10-K · filed 2023-03-30 | $11.33M 10-K · filed 2022-02-28 |
| 2021-09-30 | $11.17M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $7.64M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $5.89M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $5.54M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $4.88M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $4.90M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $5.84M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $5.58M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $4.55M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $4.52M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $3.40M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $3.06M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $4.59M 10-Q · filed 2018-11-14 | |
| 2017-12-31 | $2.90M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |